Phase 2 Start
KROS: Phase 2 Start: A Multicenter, Phase 2, Open-Label Study Evaluating the Safety and Efficacy of KER-065 in Participan
September 14, 2026 · ker-065. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 14, 2026
- Company
- Keros Therapeutics, Inc. (KROS)
- Drug
- ker-065
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Multicenter, Phase 2, Open-Label Study Evaluating the Safety and Efficacy of KER-065 in Participan
- Drug
- ker-065
- Indication
- Duchenne Muscular Dystrophy